Sihuan Pharmaceutical Holdings Group (0460) Fundamentals 2026 — P/E 39.7x, Revenue Analysis | SniperIQ
Sihuan Pharmaceutical Holdings Group (0460) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of HK$8.1B, trading at HK$0.90 on the HKSE. This SniperIQ fundamentals page covers Sihuan Pharmaceutical Holdings Group's valuation (P/E 39.7x, P/B 1.2x), profitability (net margin 6.9%), revenue (¥2.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Sihuan Pharmaceutical Holdings Group's market cap?
Sihuan Pharmaceutical Holdings Group (0460) has a market capitalization of approximately HK$8.1B, trading at HK$0.90 on the HKSE. Market cap moves with the live share price.
What is Sihuan Pharmaceutical Holdings Group's P/E ratio?
Sihuan Pharmaceutical Holdings Group's trailing twelve-month P/E ratio is 39.7x, with a price-to-book (P/B) of 1.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Sihuan Pharmaceutical Holdings Group?
Sihuan Pharmaceutical Holdings Group runs a net profit margin of 6.9%, a gross margin of 68.8%, and an operating margin of 23.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Sihuan Pharmaceutical Holdings Group generate?
Sihuan Pharmaceutical Holdings Group reported revenue of ¥2.6B for fiscal year 2025, with net income of ¥180M and earnings per share (EPS) of 0.0197. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Sihuan Pharmaceutical Holdings Group pay a dividend?
Sihuan Pharmaceutical Holdings Group offers a trailing dividend yield of about 1.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Sihuan Pharmaceutical Holdings Group financially healthy?
Sihuan Pharmaceutical Holdings Group carries a debt-to-equity ratio of 0.17x and a current ratio of 1.80x, with a market beta of 0.87. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Sihuan Pharmaceutical Holdings Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Sihuan Pharmaceutical Holdings Group (0460) the key facts are: market cap HK$8.1B, P/E 39.7x, revenue ¥2.6B, 52-week range 0.82-1.92. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Sihuan Pharmaceutical Holdings Group's full fundamentals live
Get Sihuan Pharmaceutical Holdings Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.